Clinical trial
A 16 Week Study Evaluating Levetiracetam in the Treatment of Post Herpetic…
NCT00160511 · UCB Pharma, Industry · Completed
Key facts
| NCT number | NCT00160511 |
|---|---|
| Title | A 16 Week Study Evaluating Levetiracetam in the Treatment of Post Herpetic Neuralgia (PHN) |
| Official title | A Double-blind, Randomized, Placebo-controlled, Parallel-group, 16 Week, Multicenter Trial Evaluating the Efficacy and Safety of Levetiracetam 500 mg Tablets in Bid Administration (Daily Dose Ranging From 1000 mg to 3000 mg), in Adults (≥ 18 Years of Age) Suffering From Postherpetic Neuralgia |
| Lead sponsor | UCB Pharma, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neuralgia, Postherpetic |
| Intervention type | Drug |
| Interventions | Levetiracetam |
| Enrollment | 170 |
| Start date | Apr 1, 2004 |
| Primary completion | Aug 1, 2005 |
| Completion | Sep 1, 2005 |
| First posted | Sep 12, 2005 |
| Last update posted | Nov 26, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: